Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply

N Engl J Med. 2019 May 9;380(19):1881-1882. doi: 10.1056/NEJMc1902837.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Diabetes Mellitus, Type 2*
  • Glucosides
  • Humans

Substances

  • Benzhydryl Compounds
  • Glucosides
  • dapagliflozin